Alexion Pharmaceuticals Inc (ALXN)

NASDAQ

Currency in USD

Disclaimer

182.50

0.00(0.00%)

Real-time Data20/07

Fair Value

Day's Range

180.13

182.67

52 wk Range

169.94

187.45

ALXN Income Statement

Featured here, the Income Statement (earnings report) for Alexion Pharmaceuticals Inc, showing the company's financial performance from operating and non operating activities such as revenue, expenses and income for the last 4 periods (either quarterly or annually).

Advanced Income Statement

Period Ending:

2011

31/12

2012

31/12

2013

31/12

2014

31/12

2015

31/12

2016

31/12

2017

31/12

2018

31/12

2019

31/12

2020

31/12

Total Revenues

3,084.1

3,551.1

4,131.2

4,991.1

6,069.9

Total Revenues Growth

+18.44%

+15.14%

+16.34%

+20.81%

+21.61%

Cost Of Revenues

258.3

302.1

368.5

394.5

553.5

Gross Profit

2,825.8

3,249

3,762.7

4,596.6

5,516.4

Gross Profit Growth

+19.19%

+14.98%

+15.81%

+22.16%

+20.01%

Gross Profit Margin %

91.62%

91.49%

91.08%

92.1%

90.88%

Other Operating Expenses, Total

2,032.4

2,265.7

2,142.8

2,456.7

2,635

	Other Operating Expenses, Total Growth
	R&D Expenses
	Selling General & Admin Expenses
	Other Operating Expenses

aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	+20.35%	+11.48%	-5.42%	+14.65%	+7.26%
aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	757.2	862.1	730.3	886	1,002.9
aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	953	1,083.5	1,092.4	1,261.1	1,378.4
aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	-	-	-	-	-

Operating Income

793.4

983.3

1,619.9

2,139.9

2,881.4

Operating Income Growth

+16.3%

+23.93%

+64.74%

+32.1%

+34.65%

EBIT Margin %

25.73%

27.69%

39.21%

42.87%

47.47%

Net Interest Expenses

-86

-79.9

-32.9

22.5

-60

Net Interest Expenses Growth

-118.83%

+7.09%

+58.82%

+168.39%

-366.67%

Interest Expense, Total

-96.9

-98.4

-98.2

-77.8

-104.7

Interest And Investment Income

10.9

18.5

65.3

100.3

44.7

Other Non Operating Expenses, Total

-5.2

2.9

5.4

32.8

2.7

EBT, Excl. Unusual Items

702.2

906.3

1,592.4

2,195.2

2,824.1

Gain (Loss) On Sale Of Assets

-

-

-

-

14.8

Other Unusual Items, Total

-120.7

-72

-1,299.5

-4.4

-2,142

EBT, Incl. Unusual Items

576.2

547.8

242.2

2,178.8

569

EBT, Incl. Unusual Items Growth

+15.68%

-4.93%

-55.79%

+799.59%

-73.88%

EBT, Incl. Unusual Items Margin

18.68%

15.43%

5.86%

43.65%

9.37%

Income Tax Expense

176.8

104.5

164.6

-225.5

-34.4

Net Income to Company

399.4

443.3

77.6

2,404.3

603.4

Minority Interest

-

-

-

-

-

Net Income

399.4

443.3

77.6

2,404.3

603.4

Net Income Growth

+176.59%

+10.99%

-82.49%

+2,998.32%

-74.9%

Net Income Margin %

12.95%

12.48%

1.88%

48.17%

9.94%

Preferred Dividend and Other Adjustments

-

-

-

-

-

Net Income to Common Excl. Extra Items

399.4

443.3

77.6

2,404.3

603.4

Basic EPS - Continuing Operations

1.78

1.98

0.35

10.77

2.74

Basic EPS - Continuing Operations Growth

+163.15%

+11.19%

-82.4%

+2,991.39%

-74.55%

Diluted EPS - Continuing Operations

1.76

1.97

0.35

10.7

2.72

Diluted EPS - Continuing Operations Growth

+162.69%

+11.93%

-82.31%

+2,970.74%

-74.58%

Basic Weighted Average Shares Outstanding

224.3

223.9

222.7

223.2

220.1

Diluted Weighted Average Shares Outstanding

226.3

225.4

224.5

224.8

222

Dividend Per Share

-

-

-

-

-

Dividend Per Share Growth

-

-

-

-

-

EBITDA

1,167.1

1,454.8

1,999.8

2,496.4

3,189.7

EBITDA Growth

+39.14%

+24.65%

+37.46%

+24.83%

+27.77%

EBITDA Margin %

37.84%

40.97%

48.41%

50.02%

52.55%

EBIT